

ALLERGAN INC  
Form 4  
March 19, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Hindman James M.

2. Issuer Name and Ticker or Trading Symbol  
ALLERGAN INC [AGN]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
2525 DUPONT DRIVE  
  
(Street)

3. Date of Earliest Transaction  
(Month/Day/Year)  
03/17/2015

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
EVP, Finance & Bus. Dev., CFO

IRVINE, CA 92612

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2015		G	V	2,174	D	\$ 0
Common Stock	03/17/2015		A		11,273.669 (1)	A	\$ 0
Common Stock	03/17/2015		D		32,320.305 (2)	D	(2) 0
Common Stock	03/17/2015		D		6,495.2496 (2)	D	(2) 0
Common Stock	03/17/2015		D		6,044.7258 (2)	D	(2) 0
						I	By 401(k)
						I	By ESOP

Edgar Filing: ALLERGAN INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Security (Instr. 3 and 4)	Amount of Shares
					(A)	(D)	Date Exercisable	Expiration Date		
Employee Stock Option (Right to Buy)	\$ 55.98	03/17/2015		D		18,000	(3)	02/06/2016	Common Stock	18,000
Employee Stock Option (Right to Buy)	\$ 58.55	03/17/2015		D		19,000	(3)	02/02/2017	Common Stock	19,000
Employee Stock Option (Right to Buy)	\$ 64.47	03/17/2015		D		17,600	(3)	02/14/2018	Common Stock	17,600
Employee Stock Option (Right to Buy)	\$ 40.16	03/17/2015		D		22,300	(3)	02/20/2019	Common Stock	22,300
Employee Stock Option (Right to Buy)	\$ 59.13	03/17/2015		D		18,950	(3)	02/22/2020	Common Stock	18,950
Employee Stock Option (Right to Buy)	\$ 75.58	03/17/2015		D		19,000	(3)	02/17/2021	Common Stock	19,000

Employee Stock Option (Right to Buy)	\$ 87.91	03/17/2015	D	15,500	(3)	02/17/2022	Common Stock	1
Employee Stock Option (Right to Buy)	\$ 105.87	03/17/2015	D	14,000	(3)	02/21/2023	Common Stock	14
Employee Stock Option (Right to Buy)	\$ 105.87	03/17/2015	D	1,000	(3)	02/21/2023	Common Stock	1
Employee Stock Option (Right to Buy)	\$ 125.07	03/17/2015	D	12,057	(3)	02/21/2024	Common Stock	12
Restricted Stock Units	(4)	03/17/2015	D	11,273.669	(4)	10/29/2024	Common Stock	11,2
Restricted Stock Units	(5)	03/17/2015	D	511	(5)	(5)	Common Stock	

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Hindman James M. 2525 DUPONT DRIVE IRVINE, CA 92612			EVP, Finance & Bus. Dev., CFO	

## Signatures

/s/ Matthew J. Maletta, attorney-in-fact for James M. Hindman 03/18/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Represents 11,271 performance-based restricted stock units granted on October 29, 2014 and 2,699 dividend equivalent rights acquired (1) with respect to each vested restricted stock unit (collectively, the "RSUs"). The RSUs vested in full on the Effective Date pursuant to the terms of the Merger Agreement (each as defined below).

## Edgar Filing: ALLERGAN INC - Form 4

(2) Pursuant to that certain Agreement and Plan of Merger dated November 16, 2014, (the "Merger Agreement") by and among the Issuer, Actavis, Plc ("Actavis") and a wholly-owned subsidiary of Actavis, the Issuer became an indirect wholly-owned subsidiary of Actavis upon consummation of the merger (the "Effective Date"). Each share of common stock was disposed of in exchange for \$129.22 cash plus 0.3683 of an Actavis ordinary share, having a market value of \$307.51 per share on the Effective Date.

(3) Each option vested in full on the Effective Date and was cancelled in exchange for a cash payment equal to the number of shares subject to the option immediately prior to the merger, multiplied by the difference between (i) 0.3683 times \$294.1509 (which represents the 10-day volume weighted average price of Actavis stock starting on the 11th trading day prior to the closing) plus \$129.22 and (ii) the exercise price of the option, subject to the applicable withholding taxes and pursuant to the procedures set forth in the merger.

(4) Represents 11,271 restricted stock units and 2.669 dividend equivalent rights acquired with respect to each vested stock units. The restricted stock units ("RSUs") vested in full on the Effective Date and each RSU was cancelled in exchange for 0.3638 shares of Actavis stock having a market value of \$307.51 per shares, on the Effective Date, and \$129.22 in cash.

(5) The restricted stock units ("RSUs") vested in full on the Effective Date and each RSU was cancelled in exchange for 0.3683 shares of Actavis stock having a market value of \$307.51 per share on the Effective Date, and \$129.22 in cash.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.